Universe Pharmaceuticals (NASDAQ:UPC) Announces Earnings Results

Universe Pharmaceuticals (NASDAQ:UPC) released its quarterly earnings data on Wednesday. The company reported ($1.38) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $4.52 million during the quarter.

Universe Pharmaceuticals Price Performance

Shares of NASDAQ:UPC traded up $0.07 on Wednesday, hitting $3.26. The company had a trading volume of 63,025 shares, compared to its average volume of 636,139. The stock has a 50 day moving average price of $4.01 and a 200 day moving average price of $3.48. Universe Pharmaceuticals has a 1-year low of $2.00 and a 1-year high of $17.96.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Universe Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

About Universe Pharmaceuticals

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.